Plus: FDA clears Livi as a novel vaginal health device, and demand for menopause care fuels a rapidly expanding marketplace of treatments.
Essity acquired Kenvue's feminine care business in Brazil for USD 284 million, impacting menstrual health product providers in the Brazilian market. Simultaneously, the FDA cleared Livi as a novel device supporting vaginal health on March 24, 2026, creating regulatory implications for femtech manufacturers and clinicians. These developments underscore continued market shifts driven by acquisitions and regulatory actions across the sector. Five takes inside, plus a quick-hits roundup.
Essity will acquire Kenvue’s feminine care business in Brazil for USD 284 million. This acquisition includes the Carefree, Sempre Livre, and o.b. brands. This transaction impacts the competitive landscape for menstrual health product providers in the Brazilian market.
Read the full story →A surge in demand for menopause care fuels a rapidly expanding marketplace of treatments. This market growth necessitates examination of the evidence supporting emerging approaches. Femtech operators and investors should note the continued opportunity in this expanding sector.
Read the full story →Entera Bio secured US$275 million to advance an oral osteoporosis drug for postmenopausal women, with plans for Phase III trials involving 750 participants and potential FDA application. ChronicleBio raised US$15 million to tackle POTS and other chronic diseases with AI, identifying five biologically distinct subgroups. AbCellera’s share price jumped 32% after reporting promising Phase 2 results for its non-hormonal menopause treatment, ABCL635. Midi Health, having treated more than 450,000 patients, expands beyond menopause care into PMOS and metabolic health.
Read the full story →On March 24, 2026, the FDA cleared Livi as a novel device supporting vaginal health. This regulatory action impacts manufacturers and clinicians in the femtech industry.
Read the full story →Sera Prognostics Inc. appointed Scott Gleason Chief Financial Officer on August 19, 2026. The Nasdaq-traded company (SERA) focuses on maternal and neonatal health, providing innovative pregnancy biomarker information to doctors and patients. This personnel change affects leadership at a company vital to the maternal health sector.
Read the full story →